FTC OKs $1.6B King, Alpharma Deal With Divestiture
The pharmaceutical was sold to generic-drug maker Actavis, which the FTC said should allow competition between Kadian and King’s long-acting opioid, Avinza. That competition would have been lost as a result of the acquisition, the FTC maintained.
King said Tuesday that it had completed the divestiture of Kadian in...
To view the full article, register now.